ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation

Aly Abdel-Moety; Nahed Baddour; Perihan Salem; Amr Rady; Assem El-Shendidi

doi:10.5114/ceh.2022.114172

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 8

Send email

Copy url:

abstract:

Original paper

ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation

Aly Abdel-Moety

¹

,

Nahed Baddour

²

,

Perihan Salem

¹

,

Amr Rady

³

,

Assem El-Shendidi

¹

Department of Internal Medicine (Hepatology Division), Faculty of Medicine, Alexandria University, Egypt
Department of Pathology, Faculty of Medicine, Alexandria University, Egypt
Department of Internal Medicine, Hepato-Gastroenterology and Fever Hospital in Alexandria, Egypt

Clin Exp HEPATOL 2022; 8, 1: 49-59

DOI: https://doi.org/10.5114/ceh.2022.114172

Online publish date: 2022/03/23

View full text Get citation

PlumX metrics:

Aim of the study
AT-rich interactive domain 1A (ARID1A) is a subunit of the switch/sucrose non-fermentable chromatin remodeling complex, which is commonly mutated in human cancers. The clinical and pathological significance of ARID1A alteration in hepatocellular carcinoma (HCC) has not yet been clarified. The present study aimed to evaluate the clinical significance of the ARID1A gene signature in HCC and its relation to the likelihood of tumor recurrence after microwave ablation (MWA).

Material and methods
This study included 50 patients with cirrhotic HCC of Barcelona Clinic Liver Cancer stages 0/A eligible for MWA. Tumor and peri-tumor biopsies were obtained just prior to MWA and assessed for tumor pathological grade and ARID1A expression by immunohistochemistry. Patients were followed for one year after complete tumor ablation to detect any recurrence.

Results
Tumor size (MCp = 0.010) and a-fetoprotein level (p = 0.013) can effectively predict the response to MWA. Nuclear expression of ARID1A was significantly lower in HCC compared to the corresponding peri-tumor cirrhotic liver tissues (p = 0.002), but no significant difference in ARID1A cytoplasmic expression was found. Nuclear ARID1A expression level in HCC showed a significantly negative relation to tumor size (MCp = 0.006), pathological grade (MCp = 0.046) and post-MWA tumor recurrence (FEp = 0.041).

Conclusions
ARID1A loss may enhance HCC aggressiveness and post-MWA tumor recurrence. ARID1A could be a potential target to select HCC patients for future therapies.

keywords:

ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation

Aly Abdel-Moety 1 , Nahed Baddour 2 , Perihan Salem 1 , Amr Rady 3 , Assem El-Shendidi 1

ARID1A, hepatocellular carcinoma, microwave ablation, tumor recurrence

Aly Abdel-Moety

¹

,

Nahed Baddour

²

,

Perihan Salem

¹

,

Amr Rady

³

,

Assem El-Shendidi

¹